Geron Corp. buy klostergang
Start price
26.06.15
/
50%
€3.58
Target price
07.12.15
€4.50
Performance (%)
29.46%
End price
07.12.15
€4.63
Summary
This prediction ended on 07.12.15 with a price of €4.63. The BUY prediction by klostergang finished with a performance of 29.46%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 8.560% | 8.560% | -60.726% | -58.785% |
| iShares Core DAX® | 2.331% | 5.140% | 25.000% | 65.619% |
| iShares Nasdaq 100 | 2.077% | 2.956% | 8.935% | 111.545% |
| iShares Nikkei 225® | 2.759% | 7.214% | 22.171% | 56.683% |
| iShares S&P 500 | 1.613% | 2.893% | 6.249% | 68.722% |
Comments by klostergang for this prediction
In the thread Geron Corp. diskutieren
Mit JNJ-Partnerschaft und Orphan Drug der FDA gegen Krebs :
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.
(Vom Mitglied beendet)


